Recombinant Human Adenovirus

Japan's health ministry committee has approved Teserpaturev, the country's first virotherapy drug developed by Daiichi Sankyo, marking a significant breakthrough in cancer treatment.

This article reviews the progress in clinical trials of oncolytic viruses (OVs) for cancer treatment, highlighting their safety, effectiveness, and the challenges faced in their development. OVs selectively infect and kill cancer cells without harming normal cells, showing promise in treating various tumors with mild adverse events.